Promises and pitfalls of anti-angiogenic therapy in clinical trials
Authors:
- Wenbiao LiuWLWenbiao Liu
- Fan FanFFFan Fan
- Alex ParikhAPAlex Parikh
- Niels ReimuthNRNiels Reimuth
- Oliver StoeltzingOSOliver Stoeltzing
- Lee M EllisLELee M Ellis
- 1 February 2003
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 9 (2) , 53-58
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1Nature Medicine, 2002
- Suppression of Tumor Lymphangiogenesis and Lymph Node Metastasis by Blocking Vascular Endothelial Growth Factor Receptor 3 SignalingJNCI: Journal of the National Cancer Institute, 2002
- Developmental roles of platelet‐derived growth factorsBioEssays, 2001
- Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survivalThe FASEB Journal, 2001
- The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical developmentJournal of Clinical Investigation, 1999
- Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth FactorCell, 1998
- Platelet‐derived growth factor‐B increases colon cancer cell growth in vivo by a paracrine effectJournal of Cellular Physiology, 1995
- Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.Journal of Clinical Investigation, 1995
- The extracellular matrix as a cell survival factor.Molecular Biology of the Cell, 1993
- Integrins: Versatility, modulation, and signaling in cell adhesionCell, 1992